StockIQpro
NASDAQ:NVCT

Nuvectis Pharma, Inc.

Track all markets on TradingView
Track all markets on TradingView

Nuvectis Pharma, Inc. reported net income of −$26.4M in fiscal 2025. The diluted share count rose 27.5%.Summary generated from Nuvectis Pharma, Inc.'s SEC filings. Latest annual report filed Feb 11, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−188.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+27.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−13−19−23−20−28
Net income−13−19−22−19−26
Free cash flown/an/an/an/an/a

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations